1st European Cancer Dependency Map Symposium successfully concluded in Milan on May 9th, sponsored by Nerviano Medical Sciences S.r.l.
Nerviano 9 May 2023_ Nerviano Medical Sciences Srl (NMS) was delighted to be the title sponsor of the 1st European Cancer Dependency Map Symposium, together with Astra Zeneca. This is an international event organized by scientists at Human Technopole, EMBL – European Bioinformatics Institute (Cambridge, UK), Wellcome Sanger Institute (Cambridge, UK) and ETH Zurich (Switzerland) […]
Nerviano Medical Sciences included as AACR 2023 Plenary Session highlights for its NMS-03592088 Phase 1 Clinical Trial Data in Patients with FLT3 positive Relapsed or Refractory Acute Myeloid Leukemia
Nerviano 21 April 2023_Nerviano Medical Sciences Srl, a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, is delighted to be included as Plenary Session highlights of the AACR (American Association for Cancer Research) Annual Meeting 2023 for the data from the First-In-Human study of […]
Nerviano Medical Sciences Announces Phase 1 Clinical Trial Data for NMS-03592088 in Patients with FLT3 positive Relapsed or Refractory Acute Myeloid Leukemia
Nerviano 16 April 2023_Nerviano Medical Sciences Srl, a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that data from the First-In-Human study of NMS-03592088, a novel, potent inhibitor of FLT3, KIT and CSF1R were presented during an oral scientific session at the […]
NMS Group certified as “Workplace that promotes health initiatives” again in 2022
Nerviano, 05/04/2023 NMS Group certificato di nuovo come “Luogo di lavoro che promuove salute” nel 2022 NMS group dal 2017 aderisce con gran orgoglio al programma WHP , progetto di Regione Lombardia e ATS Città Metropolitana di Milano che si pone come obiettivo la promozione della salute e il benessere nei luoghi di lavoro. Anche […]
Nerviano Medical Sciences S.r.l. to Present New Preclinical Data for NMS-812 and NMS-0963 at the American Association for Cancer Research (AACR) 2023 Annual Meeting
Nerviano Medical Sciences S.r.l. to Present New Preclinical Data for NMS-812 and NMS-0963 at the American Association for Cancer Research (AACR) 2023 Annual Meeting NMS-812: A potent and selective PERK/GCN2 inhibitor, a potential first-in-class targeting the ISR entered FIH clinical trial mid-2022 NMS-0963: A selective and orally available Syk inhibitor with promising preclinical activity in […]
Nerviano Medical Sciences S.r.l. Announces Clinical Data on NMS-03592088 selected for Oral Presentation at AACR Annual Meeting 2023
NERVIANO, 4 April 2023 – Nerviano Medical Sciences Srl (Company), a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that data from the Phase I/II clinical study of NMS-03592088 in Acute Myeloid Leukemia will be reported in an oral presentation by Dr. […]
Nerviano Medical Sciences Appointed Anders Elm Pedersen, MD, PhD, DMSc, as Senior Medical Director to accelerate further the Global Clinical Development progress
NERVIANO, IT March 1st 2023_Nerviano Medical Sciences Srl (NMS Srl), a member of NMS Group, the largest oncological R&D company in Italy, focused on the discovering and developing innovative therapies for the treatment of cancer, today announced that Anders Elm Pedersen MD, PhD, DMSc., has joined Global Clinical Development as Senior Medical Director to lead […]
Nerviano Medical Sciences Appointed Gergely Balint MSc to Accelerate MPS1 Inhibitor Asset Development
NERVIANO, IT and BOSTON, Mass, 01 February 2023_Nerviano Medical Sciences Srl (NMS Srl), a member of NMS Group, the largest oncological R&D company in Italy, focused on the discovering and developing innovative therapies for the treatment of cancer, today announced that Gergely Balint, MSc, has joined the Global Asset Leadership Team to lead the development […]
Nerviano Medical Sciences Strengthens Executive Team to Maximize IDH1/IDH2 Inhibitor Asset – Terrence West, MBA, joins as New Business, Virtual CEO
NERVIANO, IT and BOSTON, Mass, January 12, 2023 – Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group), focused on the discovery and early development of oncology drugs and the largest oncological R&D company in Italy, announced today the senior appointment to drive validation and maximize the value of its IDH1/IDH2 Inhibitor […]
MPS1 (NMS-01940153E) Kinase Inhibitor Shows Clinical Activity in Primary Liver Cancer
NEWS MPS1 Kinase Inhibitor Shows Clinical Activity in Primary Liver Cancer The targeted drug NMS-01940153E, a monopolar spindle 1 (MPS1) kinase inhibitor, has shown signs of clinical activity in a Phase I study of patients with relapsed or refractory unresectable hepatocellular carcinoma (HCC). The study findings were reported at the 34th EORTC-NCI-AACR Symposium […]
